Webinars and Sponsored Roundtables — Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

August 2025

Put It on the Board

August 2025—In a position statement released in July, the CAP urged policymakers to consider scientific and logistical evidence and to protect the integrity and safety of the national blood supply. The statement was issued in response to legislation proposed in several states that would require blood product labeling based on donor vaccination status or mandate hospitals and blood collectors to honor requests for directed and autologous donations. Misinformation surrounding COVID-19 and mRNA vaccines has led to a growing number of patient requests for blood transfusions exclusively from unvaccinated donors.

Systemic Mastocytosis: Overview of Disease and Diagnosis for Pathologists

Webinar presenter Sheeja Pullarkat, MD, on behalf of Blueprint Medicines, Professor of Pathology and Laboratory Medicine, Director of Hematopathology Fellowship Program, Hematopathology and Hematology, UCLA Health, discusses Systemic Mastocytosis (SM), SM evaluation and diagnostic work-up, and technical challenges and best practices for optimizing testing. Moderated by Bob McGonnagle, Publisher, CAP TODAY. This on-demand webinar originally broadcast June 2, 2022.

Community-based rapid NGS offers considerable advantages in clinical cancer care

Webinar presenter Brandon Sheffield, MD, Anatomic and Molecular Pathologist, Department of Laboratory Medicine, William Osler Health System, discusses William Osler Health System’s experience with implementing next-generation sequencing (NGS) in routine oncology biomarker testing. In their pilot study, 578 pan-cancer solid tumor samples underwent genomic profiling. All testing was performed by one group of technologists within the same division of the laboratory, achieving a median turnaround time (TAT) of 3 business days. Dr. Sheffield will elaborate on the importance of timely availability of biomarker results for optimal cancer care, demostrate the feasibility of such TATs in community-based hospitals using fast and automated NGS, and describe the novel approach of integrating NGS with routine immunohistochemistry. Moderated by Bob McGonnagle, Publisher, CAP TODAY. This on-demand webinar originally broadcast August 3, 2022.

Methylation Analysis: A new approach to sarcoma classification

Webinar presenters Andreas von Deimling, MD, Department of Neuropathology, Institute of Pathology, University Heidelberg, and Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), and Christian Kölsche, MD, Department of General Pathology, Institute of Pathology, University Hospital Heidelberg, discuss sarcoma classification by DNA methylation profiling, principles of methylation-based tumor classification, approaches to sarcomas with methylation analysis, and practical examples and outlook of accessing the tool. Moderated by: Bob McGonnagle, Publisher, CAP TODAY. This on-demand webinar originally broadcast July 20, 2022.